Recent events
Recent events tied to this brand in public sources.
Back to profile95 entries · Page 3 of 5
2022
Bayer discontinues development of eliapixant
Bayer decided to discontinue clinical development of eliapixant, an investigational P2X3 receptor antagonist. Evotec said it regained rights to all P2X3 assets and would evaluate the data when available.
2022
Bayer launches Testing4Ag platform
Bayer launched Testing4Ag, a programme through which research scientists worldwide can submit novel chemistries to Bayer for testing for potential new ways to control fungal diseases, insect pests or weeds. Bayer says the programme provides testing and results to participants while they retain rights to potential intellectual property generated through the programme.
2021
Bayer and SAME Foundation launch COVID-19 relief fund
Bayer South East Africa launched a COVID-19 relief fund in partnership with the South Africa Medical and Education (SAME) Foundation to provide equipment and psychological support to healthcare workers.
2021
Crystal Crop completes acquisition of four Bayer hybrid seed businesses
Crystal Crop Protection completed its acquisition from Bayer in India of four hybrid seed businesses: cotton, mustard, pearl millet and grain sorghum. The acquired business includes the Proagro and Surpass brands.
2021
Jury awards $62 million in PCB exposure case
A King County jury awarded $62 million in damages to eight people harmed by exposure to PCBs at Sky Valley Education Center. The jury decided Bayer had done too little to warn the public about PCBs. Bayer Pharmaceuticals said it disagreed with the verdict and planned to appeal.
2021
Huma and Bayer collaborate on lung cancer research
Huma and Bayer announced a collaboration using machine learning to help distinguish types of non-small-cell lung cancer from CT scans and improve diagnosis.
2021
EarthOptics closes $10.3 million Series A funding round
EarthOptics closed its Series A investment round, raising an additional $10.3 million. Leaps by Bayer led the round, with Bayer and other investors also participating.
2021
FDA approves Astepro for nonprescription sale
The U.S. Food and Drug Administration approved Bayer's Astepro nasal spray for sale without a prescription.
2021
Bayer announces acquisition agreements for Noria and PSMA Therapeutics
Bayer announced that it had entered into acquisition agreements with Noria Therapeutics and PSMA Therapeutics, including rights to an actinium-225-labeled small molecule targeting PSMA for prostate cancer treatment.
2021
LHC Group files complaint against Bayer over Essure
LHC Group filed a complaint against Bayer and others concerning the allegedly defective Essure birth-control device. The plaintiff alleged that Bayer negligently monitored and reported complications and continued marketing the product as safe and effective; these are allegations in the complaint, not a court determination.
2021
GreenLight Biosciences acquires rights to Bayer topical RNA IP
GreenLight Biosciences announced that it had acquired rights to portions of Bayer's topical RNA intellectual property portfolio, including bee-health capabilities intended to protect against Varroa mites.
2021
Bayer launches Beirun skincare brand
Bayer launched the new Beirun skincare brand at the 26th China Beauty Expo, which opened on May 12.
2021
ESSA Pharma and Bayer enter clinical collaboration and supply agreement
ESSA Pharma announced that it had entered into a clinical trial collaboration and supply agreement with Bayer to evaluate EPI-7386 in combination with darolutamide in patients with metastatic castration-resistant prostate cancer. Bayer may sponsor and conduct a Phase 1/2 study; ESSA will supply EPI-7386 and retain all rights to the candidate.
2021
Bayer agrees class plan for future Roundup cases
Bayer announced a formal agreement with plaintiffs’ class counsel on a class plan designed to manage and resolve future Roundup cases.
2021
Bayer China receives 2021 Top Employer certification
Bayer China received the China Top Employer 2021 certification and ranked among the top 20 listed employers, according to the announcement.
2021
FDA approves Verquvo for adults with symptomatic chronic heart failure
The U.S. Food and Drug Administration approved Merck & Co.'s Verquvo to reduce cardiovascular death and heart failure hospitalization risk in specified adults with symptomatic chronic heart failure.
2020
Bayer and Arogya Finance announce Eylea payment partnership in India
Bayer and Arogya Finance announced a collaboration to introduce the Eylea Easy Pay Program in India, offering patients flexible payment solutions for Eylea treatment.
2020
Bayer wins 2020 Outstanding Contribution to Sustainable Development Award
Bayer won the 2020 Outstanding Contribution to Sustainable Development Award for its Healthy Vision public welfare project. The event was held the previous day, December 9, 2020.
2020
BlockApps launches TraceHarvest Network
BlockApps announced the launch of TraceHarvest, a blockchain-powered agricultural business network developed in collaboration with Bayer. Bayer was a founding member and used the network for customer-facing operations in regions including the United States and Brazil.
2020
Bayer announces Beijing plant capacity expansion
Bayer announced an investment of more than €50 million to expand capacity at its Beijing prescription medicine factory. The completed project is expected to increase annual plant capacity by about 40% and is planned to enter use by the end of 2022.